PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.98%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
38.60%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
30.20%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
30.24%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.24%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-238.96%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-238.96%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-778.56%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-778.56%
Negative 5Y OCF/share CAGR while AGEN is at 66.13%. Joel Greenblatt would question the firm’s operational model or cost structure.
-778.56%
Negative 3Y OCF/share CAGR while AGEN stands at 62.68%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-3564.11%
Negative 10Y net income/share CAGR while AGEN is at 25.33%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-3564.11%
Negative 5Y net income/share CAGR while AGEN is 64.66%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-3564.11%
Negative 3Y CAGR while AGEN is 57.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-1192.22%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-1192.22%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-1192.22%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-7.18%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
20.52%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-41.39%
We cut SG&A while AGEN invests at 5.78%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.